pancuronium

Trade name: pavulon

Small moleculeapproved

Approved

Oct 24, 1972

Pancuronium (trademarked as Pavulon) is an aminosteroid muscle relaxant with various medical uses. Pancuronium is a typical non-depolarizing curare-mimetic muscle relaxant. It competitively inhibits the nicotinic acetylcholine receptor at the neuromuscular junction by blocking the binding of acetylcholine. It has slight vagolytic activity, causing an increase in heart rate, but no ganglioplegic (i.e., blocking ganglions) activity. It is a very potent muscle relaxant drug, with an ED95 of only 60 µg/kg body weight. The onset of action is relatively slow compared to other similar drugs, in part due to its low dose - an intubating dose takes 3–6 minutes for full effect. Clinical effects (muscle activity lower than 25% of physiological) last for about 100 minutes. The time needed for full (over 90% muscle activity) recovery after single administration is about 120–180 minutes in healthy adults. Pancuronium is used with general anesthesia in surgery for muscle relaxation and as an aid to intubation or ventilation. It does not have sedative or analgesic effects. Side-effects include moderately raised heart rate and thereby arterial pressure and cardiac output, excessive salivation, apnea and respiratory depression, rashes, flushing, and sweating. The muscular relaxation can be dangerous for the seriously ill and it can accumulate leading to extended weakness. Pancuronium is not preferable to long-term use in ICU-ventilated patients. Pancuronium is also used as one component of a lethal injection in the administration of the death penalty in some parts of the United States. — NCATS

Clinical trial activity

0 trials · 0 clinical orgs · 7 marketing orgs

Phase 1
0
Phase 2
0
Phase 3
0
Phase 4
0

Timeline

1970s

  1. Oct 24, 1972

    Organon — Earliest FDA Approval

  2. Oct 24, 1972

    Organon — NDA Organization

1980s

  1. Mar 23, 1988

    Elkins Sinn — Marketing Organization

  2. Jan 19, 1989

    Hospira — Marketing Organization

1990s

  1. Jul 31, 1990

    Teva — Marketing Organization

  2. Jul 31, 1990

    Dr. Reddy's Laboratories — Marketing Organization

Indications

Mechanism of action

Approval history

  • approvedPriority reviewOct 24, 1972

Chemistry & pharmacology

Loading structure…

SMILES

CC(=O)O[C@H]1C[C@@H]2CC[C@@H]3[C@H](CC[C@@]4(C)[C@H]3C[C@H]([N+]3(C)CCCCC3)[C@@H]4OC(C)=O)[C@@]2(C)C[C@@H]1[N+]1(C)CCCCC1
Mol. weight
572.88 g/mol
Lipinski Ro5
2 violation(s)
Rule of 3
No
Chirality
Single Stereoisomer
Inorganic
No
Polymer
No
Delivery
Parenteral
Availability
Prescription Only

Oral

No

Parenteral

Yes

Topical

No

Sources

Also known as

  • bromure de pancuronium
  • bromure de pancuronium
  • bromurex
  • bromuro de pancuronio
  • bromuro de pancuronio
  • mioblock
  • mioblock
  • org na 97
  • org na 97
  • org-na 97
  • org-na 97
  • pancuronium
  • pancuronium
  • pancuronium
  • pancuronium
  • pancuronium
  • pancuronium
  • pancuronium bromide
  • pancuronium bromide
  • pancuronium bromide
  • pancuronium bromide
  • pancuronium bromide
  • pancuronium bromide
  • pancuronium bromide
  • pancuronium dibromide
  • pavulon
  • pavulon
  • pavulon

Organizations

Marketing (7)

OrganizationOrg typeRelationshipDate
Athenex, Inc.For profitMKTG
Dr. Reddy's LaboratoriesFor profitMKTGJul 31, 1990
Elkins SinnFor profitMKTGMar 23, 1988
HospiraFor profitMKTGJan 19, 1989
OrganonFor profitNDAOct 24, 1972
Teligent PharmaceuticalsFor profitMKTG
TevaFor profitMKTGJul 31, 1990